Broberger and Perlmann described for the first-time anti-goblet cell antibodies (GABs) in 1959. Sixty years later the target autoantigen of these inflammatory bowel disease (IBD)-related autoantibodies remains unknown. GABs are detected in approximately one third of patients with ulcerative colitis and Crohn’s disease. Their presence in other enteropathies is less prominent making this autoantibody IBD-related. Its diagnostic and clinical significance remains elusive. Currently, routine diagnostic serology testing of suspected patients with IBD does not include assessment of GABs. Very few laboratories report the presence of goblet cell (anti-mucin) autoantibodies and their current testing is mainly performed for research purposes.
Primary Content – Primary Content Goes Here.
Close
Τα cookies είναι σημαντικά για την εύρυθμη λειτουργία του ιστοτόπου και την βελτίωση της online εμπειρίας σας. Πατήστε "Αποδοχή" για να συνεχίσετε!
